Skip to main content

ValiRx CEO introduces Cytolytix at London South East webinar

9 Nov 2022


CEO of ValiRx Dr Suzy Dilly was pleased to present at London South East’s Investor Relations webinar yesterday (8 November 2022), to discuss the recent formation of new subsidiary company, Cytolytix Limited.

London South East is a leading resource that provides private investors with the latest industry news, share prices, and data. 

Suzy was invited to join the webinar to introduce Cytolytix, which has signed an IP licence agreement with King's College London to progress the preclinical development of its triple negative breast cancer treatment, CLX001. 

The recording of Suzy’s presentation is available to watch online here.

Click here to view the Cytolytix presentation slides. 


Suzanne Dilly